Studies in animal models and humans have identified an important role for peripheral chemoreceptors in the pathogenesis of heart failure. Thus, inhibiting their hyperactivity has been proposed as a potential therapeutic strategy for this major public health problem.
Researchers at Tuojie Biotech (Shanghai) Co. Ltd. have developed substituted 1,4-dihydro-1,6-naphthyridine amides characterized as mineralocorticoid receptor (MR) antagonists and reported to be useful for the treatment of hypertension, aldosteronism and heart failure.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Tongji Hospital have disclosed sulfonylurea compounds acting as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of heart failure.
Merck & Co. revealed the structure of an orally active and potent proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor macrocyclic peptide, MK-0616, which is being developed for the potential treatment of hypercholesterolemia and atherosclerosis.
(Azacycloalkyl)methoxy-substituted benzamides acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists have been described in a recent Accellena Research and Development LLC patent.
Ancora Heart Inc. reported 12-month data showing its Accucinch system significantly improves outcomes in heart failure (HF) patients, including positive changes in cardiac structure and function. The results, presented at the Technology and Heart Failure Therapeutics conference (THT 2023) in Boston, were simultaneously published in the Journal of Cardiac Failure.
Accellena Research and Development LLC has identified substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists reported to be useful for the treatment of cardiovascular disorders, diabetes, metabolic diseases, migraine, neurological disorders, obesity, psychiatric disorders and substance abuse and dependence.
Researchers from Baylor College of Medicine presented data from postnatal testing with the aim of providing molecular diagnosis for a patient with prenatally diagnosed heterotaxy syndrome.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified dual antagonists of endothelin ETA receptor and angiotensin AT1 receptor reported to be useful for the treatment of diabetes, hypertension and renal disorders.
RSS
